Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is dedicated to investing in scientific innovation to create transformative medicines for people with serious diseases. The company fosters a culture of innovation, inclusivity, and commitment to patients, with a focus on advancing science and medicine through continuous learning and collaboration. Vertex offers a wide range of career development programs, including internships, co-ops, fellowships, and specialized programs in science, medicine, and data sciences. The company operates globally with offices and research sites in the United States, Australia, Europe, and other regions, emphasizing diversity, community engagement, and scientific excellence.
Industries
Nr. of Employees
Very Large (1000+)
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals, 1301 Sansome Street, San Francisco, CA 94111, USA
Patents
Modified urokinase-type plasminogen activator polypeptides and methods of use
US-12331334-B2
View Details
Modified urokinase-type plasminogen activator polypeptides and methods of use
US-12331334-B2
View DetailsProducts
Cystic Fibrosis Medicines
Vertex Pharmaceuticals develops medicines for cystic fibrosis, a genetic disease affecting the lungs and digestive system.
Sickle Cell Disease Research
Vertex is involved in research and development of treatments for sickle cell disease, focusing on understanding patient experiences and advancing potential therapies.
Type 1 Diabetes Research
Vertex is investigating cellular-level treatments for type 1 diabetes, aiming to develop innovative therapies.
APOL1-Mediated Kidney Disease Research
Vertex is researching therapies for APOL1-mediated kidney disease, a genetic condition with significant unmet medical needs.
Pain Management Research
Vertex has been researching potential medicines to treat pain for over 20 years, focusing on innovative approaches.
Beta Thalassemia Research
Vertex is committed to developing treatments for beta thalassemia, a blood disorder, through ongoing research and community engagement.
Cystic Fibrosis Medicines
Vertex Pharmaceuticals develops medicines for cystic fibrosis, a genetic disease affecting the lungs and digestive system.
Sickle Cell Disease Research
Vertex is involved in research and development of treatments for sickle cell disease, focusing on understanding patient experiences and advancing potential therapies.
Type 1 Diabetes Research
Vertex is investigating cellular-level treatments for type 1 diabetes, aiming to develop innovative therapies.
APOL1-Mediated Kidney Disease Research
Vertex is researching therapies for APOL1-mediated kidney disease, a genetic condition with significant unmet medical needs.
Pain Management Research
Vertex has been researching potential medicines to treat pain for over 20 years, focusing on innovative approaches.
Beta Thalassemia Research
Vertex is committed to developing treatments for beta thalassemia, a blood disorder, through ongoing research and community engagement.
Services
Research
Vertex conducts cutting-edge research to discover new medicines and understand disease mechanisms.
Medicine Development and Medical Affairs
The company develops medicines and provides medical support to ensure effective patient care.
Pharmaceutical and Preclinical Sciences
Vertex's scientific teams work on preclinical studies and pharmaceutical sciences to bring new therapies to market.
Quality and Regulatory
Ensuring the quality of medicines and compliance with regulations is a core part of Vertex's operations.
Market Access and Public Policy
Vertex works on market access strategies and engages with public policy to support patient access.
Commercial
The commercial team focuses on bringing medicines to patients and supporting healthcare providers.
Research
Vertex conducts cutting-edge research to discover new medicines and understand disease mechanisms.
Medicine Development and Medical Affairs
The company develops medicines and provides medical support to ensure effective patient care.
Pharmaceutical and Preclinical Sciences
Vertex's scientific teams work on preclinical studies and pharmaceutical sciences to bring new therapies to market.
Quality and Regulatory
Ensuring the quality of medicines and compliance with regulations is a core part of Vertex's operations.
Market Access and Public Policy
Vertex works on market access strategies and engages with public policy to support patient access.
Commercial
The commercial team focuses on bringing medicines to patients and supporting healthcare providers.
News & Updates
Vertex's treatment for moderate-to-severe acute pain in adults has received approval from the U.S. FDA.
Vertex has published its 2024 Corporate Responsibility Report detailing its efforts in responsible business practices.
A Vertex researcher has been recognized with the 2025 Canada Gairdner International Award for pioneering research in cystic fibrosis.
Vertex announced its Q1 2025 financial results on May 5.
Recognition for pioneering research and discovery of medicines for cystic fibrosis.
Vertex's treatment for moderate-to-severe acute pain in adults has received approval from the U.S. FDA.
Vertex has published its 2024 Corporate Responsibility Report detailing its efforts in responsible business practices.
A Vertex researcher has been recognized with the 2025 Canada Gairdner International Award for pioneering research in cystic fibrosis.
Vertex announced its Q1 2025 financial results on May 5.
Recognition for pioneering research and discovery of medicines for cystic fibrosis.